浙江泉生生物科技

Zhejiang Quansheng Biotechnology is a clinical-stage biopharmaceutical company specializing in the development of mesenchymal stem cell (MSC) therapies. Headquartered in Huzhou, China, the company focuses on treating severe inflammatory and degenerative conditions, including acute-on-chronic liver failure and osteoarthritis. Quansheng Biotech maintains a comprehensive R&D system and a large-scale GMP-compliant manufacturing facility for standardized cell production. Their pipeline includes several human umbilical cord-derived MSC candidates currently undergoing clinical evaluation. The company is dedicated to advancing regenerative medicine through innovative cell-based solutions.